Commercial

MM&M's top 5 stories in November 2016

MM&M's top 5 stories in November 2016

By

How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy

Five things for pharma marketers to know: Wednesday, November 30, 2016

Five things for pharma marketers to know: Wednesday, November 30, 2016

By

Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey

Gilead's Meyers on making deals and finding unmet patient needs

Gilead's Meyers on making deals and finding unmet patient needs

By

The drugmaker's new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

By

The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.

Five things for pharma marketers to know: Tuesday, November 22, 2016

Five things for pharma marketers to know: Tuesday, November 22, 2016

By

Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

By

"This is not your grandfather's launch," said Shawn Tomasello, chief commercial officer of Kite Pharma.

Will he or won't he? Pharma speculates on President-elect Trump

Will he or won't he? Pharma speculates on President-elect Trump

By

If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.

Pharma pushes to share off-label info with payers at FDA hearing

Pharma pushes to share off-label info with payers at FDA hearing

By

Insurers and pharmacy benefit managers already have a sophisticated understanding of clinical data, the industry argued.

The drug industry wins pricing battle in California, likely to fare better with Trump

The drug industry wins pricing battle in California, likely to fare better with Trump

By

But experts say that drug pricing will remain a significant issue for the industry going forward into a non-election year.

With more marketing spend behind it, Eliquis gains on market leader Xarelto

With more marketing spend behind it, Eliquis gains on market leader Xarelto

By

BMS and Pfizer outspent Johnson & Johnson two-to-one in advertising for their oral anticoagulant last year.

Drugmakers, facing pricing criticism, sell cures in new ads

Drugmakers, facing pricing criticism, sell cures in new ads

By

With lawmakers, patients, and physicians crying foul over pricing, drugmakers are trying to shift the narrative — with mixed results. Can a new focus on storytelling help?

Five things for pharma marketers to know: Friday, October 28, 2016

Five things for pharma marketers to know: Friday, October 28, 2016

By

Repatha and Praluent launches described by analyst as waste of money; AstraZeneca halts trial for cancer drug; health exchange choices dwindle

New science drives biopharma interest in neurological conditions

New science drives biopharma interest in neurological conditions

By

The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.

J&J exec calls California pricing measure 'misguided'

J&J exec calls California pricing measure 'misguided'

By

Voters are set to vote on Proposition 61, which would allow state agencies to pay the same prices for drugs that the VA department pays.

Will Investors Reward Drugmakers That Limit Price Increases?

Will Investors Reward Drugmakers That Limit Price Increases?

By

Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?

Five things for pharma marketers to know: Friday, October 21, 2016

Five things for pharma marketers to know: Friday, October 21, 2016

By

Lawmakers ask for information about price of leukemia drug; Abbott writes down losses from Mylan stake; CVS Health focused on role as health brand

Merck outspends Bristol-Myers Squibb on journal ads for Keytruda

Merck outspends Bristol-Myers Squibb on journal ads for Keytruda

By

Merck doled out more than $2 million to target doctors in the first half of the year, while BMS spent only $863,000.

Five things for pharma marketers to know: Monday, October 3, 2016

Five things for pharma marketers to know: Monday, October 3, 2016

By

More drugmakers file lawsuits to prevent biosimilar competition; experimental dermatitis drug showeds promising results; pharma blames PBMs for price hikes

Five things for pharma marketers to know: Wednesday, September 28, 2016

Five things for pharma marketers to know: Wednesday, September 28, 2016

By

Patient advocacy groups stay silent in drug-pricing debate; Opdivo to be tested in combination with Nektar drug; 25% of FDA employees now work for industry

The FDA, Astellas, and Accenture use innovation competitions to help address business challenges

The FDA, Astellas, and Accenture use innovation competitions to help address business challenges

By

The organizations are using innovation competitions to challenge internal and external audiences with coming up with new ideas.

The FDA approves Amgen's biosimilar version of Humira

The FDA approves Amgen's biosimilar version of Humira

By

Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.

4 Ways for Marketers To Differentiate Their Brands In The Rare-Disease Space

4 Ways for Marketers To Differentiate Their Brands In The Rare-Disease Space

Data analytics, relationship building, and improved patient support are the keys to differentiating your rare-disease drug brands, according to these four marketers.

Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?

Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?

By

One analyst envisions how a first-line approval could set up Keytruda for success in other settings.

CEO: Allergan will limit price increases for branded drugs

CEO: Allergan will limit price increases for branded drugs

By

CEO Brent Saunders also said the drugmaker will not increase the price of drugs nearing patent expiration.

Data, Technology, and Medicine: How They Intersect

Data, Technology, and Medicine: How They Intersect

By

The intersection of data, technology, and medicine is rapidly changing how doctors practice, drug companies market, and patients engage with the healthcare system.

Drugmakers revive R&D focus on long stagnant women's health market

Drugmakers revive R&D focus on long stagnant women's health market

By

Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?

Long neglected, the osteoporosis market prepares for new entrants

Long neglected, the osteoporosis market prepares for new entrants

By

The osteoporosis drug market is bracing for the advent of potentially game-changing treatments.

Top 25 women's health products, ranked by 2016 forecasts

Top 25 women's health products, ranked by 2016 forecasts

Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

By

Only one new osteoporosis drug has been approved over the last six years.

Five things for pharma marketers to know: Friday, August 12, 2016

Five things for pharma marketers to know: Friday, August 12, 2016

By

Study finds estimated drug costs are often overstated; physician criticizes DTC ad for Opdivo; Merck HPV ads are criticized for being manipulative

OPINION

Email Newsletters